L26/O-163 Precise time to trophectoderm biopsy predicts ploidy and euploid embryo outcomes: a continuous analysis using operator-independent radiofrequency identification witnessing
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Quintana-Vehi und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Is the precise timing of trophectoderm biopsy, measured using an automatic operator-independent radiofrequency identification (RFID) witnessing system, associated with PGT-A outcomes, including euploid embryo competence? Summary answer Each additional hour to biopsy was associated with 2.4% higher odds of aneuploidy and, in euploid embryos, 2.8% lower odds of live birth. What is known already PGT-A requires extended embryo culture to the blastocyst stage, typically between day 5 and day 7. Several reports have demonstrated higher euploidy rates and improved clinical outcomes for blastocysts biopsied on day 5 compared to those biopsied on day 6 or day 7. However, existing studies categorise embryos by biopsy day rather than the precise time elapsed from ICSI to trophectoderm biopsy. This categorical approach overlooks substantial variability in actual culture duration among embryos within the same day category. Consequently, the true association between culture time, aneuploidy risk, and clinical outcomes remains unclear. Study design, size, duration This retrospective cohort study analysed 2,903 embryos from 734 PGT-A cycles performed at a single IVF centre between January 2021 and December 2024. Exact times from ICSI to biopsy were recorded automatically using an operator-independent RFID electronic witnessing system. Key morphokinetic timepoints (tSB and tB) were captured using time-lapse imaging. All embryos underwent PGT-A by a single genetic testing provider, ensuring methodological consistency across the study period. Participants/materials, setting, methods The association between PGT-A results, clinical outcomes, culture duration, and morphokinetic timepoints was evaluated using mixed-effects logistic regression accounting for within-patient clustering, adjusting for maternal age and oocyte origin. Biopsy timing was primarily modelled as a continuous variable, with secondary categorical classification using Istanbul consensus groups: before day 5 (<114h), day 5 (114-118h), between days 5-6 (118-142h), day 6 (142-146h), and after day 6 (>146h). Clinical outcomes were assessed in 310 single euploid embryo transfers. Main results and the role of chance Mean maternal age (±SD) was 38.5 (±4.3) years, with an overall euploidy rate of 37.9%. Biopsy timing varied considerably across Istanbul consensus categories: 6.4% of embryos were biopsied before day 5, 32.2% on day 5, 36.8% between days 5-6, 15.5% on day 6, and 9.2% after day 6. Corresponding euploidy rates were 37.3%, 40.6%, 40.8%, 30.1%, and 30.0%, respectively. When modelled continuously, each additional hour of culture increased the odds of aneuploidy by 2.4% (OR = 1.024, 95%CI: 1.015-1.032, p < 0.0001). Morphokinetic parameters mirrored this pattern, with delayed blastulation (tSB) and delayed full blastocyst formation (tB) independently predicting aneuploidy (tSB: OR = 1.014, [95%CI: 1.004-1.024], p = 0.005; tB: OR = 1.023, [95%CI: 1.014-1.032], p < 0.0001). Notably, blastocyst expansion time (tB-tSB) predicted both aneuploidy (OR = 1.042, [95%CI: 1.024-1.059, p < 0.0001), as well as lower live birth rates in euploid embryo transfers (OR = 0.905, [95%CI: 0.897-0.913], p < 0.0001). Critically, among euploid embryos, each additional hour to biopsy reduced the odds of implantation by 4.2% (OR = 0.958, [95%CI: 0.932-0.986], p = 0.003) and the odds of live birth by 2.8% (OR = 0.972, [95%CI: 0.969-0.976], p < 0.0001). Interestingly, embryos biopsied before day 5 achieved the highest live birth rate (81.8%) despite lower euploidy rates (37.3%). These findings demonstrate that both culture duration and expansion dynamics compromise embryo competence independently of ploidy status. Limitations, reasons for caution The retrospective single-centre design may limit generalisability. Unmeasured confounders are possible despite statistical adjustments. Prospective multicentre validation with a larger transfer cohort is warranted to strengthen these findings. Wider implications of the findings This study shifts the paradigm from categorical day-based analysis to a continuous developmental model. Precise biopsy timing, automatically recorded via RFID, may offer an objective readily available marker of embryo competence that complements PGT-A. These findings support standardised reporting of exact culture duration to refine embryo selection and patient counselling. Trial registration number No
Zitieren
APA
Quintana-Vehi, A., Skojo, M., Zamora, M., Popovic, M., Miguel-Escalada, I., & Rodriguez-Aranda, A. (2026). L26/O-163 Precise time to trophectoderm biopsy predicts ploidy and euploid embryo outcomes: a continuous analysis using operator-independent radiofrequency identification witnessing. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.161
Vancouver
Quintana-Vehi A, Skojo M, Zamora M, Popovic M, Miguel-Escalada I, Rodriguez-Aranda A. L26/O-163 Precise time to trophectoderm biopsy predicts ploidy and euploid embryo outcomes: a continuous analysis using operator-independent radiofrequency identification witnessing. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.161
BibTeX
@article{QuintanaVehi2026,
author = {Quintana-Vehi, A. and Skojo, M. and Zamora, M.J. and Popovic, M. and Miguel-Escalada, I. and Rodriguez-Aranda, A.},
title = {L26/O-163 Precise time to trophectoderm biopsy predicts ploidy and euploid embryo outcomes: a continuous analysis using operator-independent radiofrequency identification witnessing},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.161}
}
EUVIMED